To validate these results, we performed a parallel analysis based on ACSL3, NID1, and RETN expression in larger series of NSCLC samples from The Cancer Genome Atlas (TCGA) study, a publicly available gene expression dataset (https://www.cancer.gov/tcga). This evidence concerns the gene NID1 and non-small cell lung carcinoma.